UC researcher receives patent for new breast cancer treatment
October 25, 2021
The University of Cincinnati's Dr. Xiaoting Zhang has been awarded a patent for a novel RNA nanoparticle treatment for breast cancer.
October 25, 2021
The University of Cincinnati's Dr. Xiaoting Zhang has been awarded a patent for a novel RNA nanoparticle treatment for breast cancer.
October 11, 2021
The University of Cincinnati is opening a new clinical trial looking to see how the combination of immunotherapy and transplant can improve patient outcomes.
November 29, 2021
University of Cincinnati's Dr. Robert Van Haren recently published new research that shows lung cancer surgery outcomes between former and current smokers are similar enough that smoking should not be a barrier to offering surgery.
January 4, 2022
The University of Cincinnati's Dr. Ishita Basu is researching how targeted electrical stimulation can be used as a treatment for mental health disorders.
September 30, 2021
University of Cincinnati researchers have joined a nationwide clinical trial exploring the effectiveness of personalized treatments for patients with acute myelogenous leukemia (AML), a cancer of the blood and bone marrow.
November 16, 2021
Researchers at the University of Cincinnati are leading the largest-ever NIH stroke recovery study, examining if certain biomarkers can help predict patient recovery.
December 9, 2021
University of Cincinnati researchers are leading the FASTEST global trial that will examine the effectiveness of a new treatment for strokes due to intracerebral hemorrhage.
October 14, 2021
UC's Dr. Annie Brown discusses breast cancer screening recommendations for transgender patients and ways to make care more accessible and equitable.
February 25, 2022
University of Cincinnati researchers led by Jiajie Diao and Yujie Sun have developed a new pH probe and imaging technique to provide researchers more information when studying diseases like cancer and Alzheimer's.
February 28, 2022
Researchers led by the University of Cincinnati's Dr. Trisha Wise-Draper led a clinical trial that showed immunotherapy drug pembrolizumab increased survival rates for head and neck cancer patients with intermediate risk.